valu usd unless otherwis note
guidanc demonstr strength divers
view product cycl refresh medic devic diagnost cost
synergi stj alr capit deploy acceler debt
repay push abt revenu ep growth ahead sever
med-tech peer share reward premium
valuat manag optimist tone strength portfolio
suggest top half guidanc realist rais pt
 growth improv aid better expect result
three segment ww revenu y/i
compar basi estim growth
slow acceler medic devic
cardiovascular neuromodul sale growth rose
diagnost exclud alr grew nutrit
 sale increas diabet help
launch freestyl libr cgm grew compar
declin revenu y/i exclud fx
diagnost cardiovascular neuromodul
primari factor slightli faster revenu growth
cardiovascular neuromodul benefit recent
product approv strong end market ww revenu
growth newli creat product categori follow
close stj transact rhythm manag rm
sale slump y/i heat failur hf sale fell
 ww revenu increas rm sale increas
ww hf sale grew ww new product
mr-condit icd pacemak heartmat lvad
drove revers fortun busi electrophysiolog
structur heart neuromodul among fastest-grow
organ revenu growth guidanc better
expect analysi indic organ growth would
exceed three four segment medic devic
diagnost establish pharmaceut could grow collect
least issu guidanc organ growth express
confid top half rang achiev rel
assumpt guidanc medic devic stood mid- high-
single-digit interpret base commentari
confer call believ four segment achiev revenu
growth close high end guidanc
increas estim new pt
new revenu estim prior
estim impli underli growth approxim
increas revenu estim
spread across four segment ep estim
prior abt ep guidanc
price prior trade day market close estimate unless otherwis note
cours double-digit ep growth
product cycl refresh medic devic
diagnost cost synergi stj alr capit
deploy acceler debt repay push
abt revenu ep growth ahead sever med-tech
peer revenu estim impli
underli growth ep
estim repres growth
product product approv provid
impetu faster growth medic devic
among signific approv
mr-condit icd septemb mr-condit
crt-d januari receiv approv mr-
condit pacemak februari result
approv rhythm manag product categori
return growth electrophysiolog structur
heart neuromodul among fastest-grow
virtu compet fast-grow end market
shape excit year diagnost
well close alr transact add diagnost
portfolio receiv fda approv
first two instrument new alin platform
laboratori diagnost other
forthcom come month alin suit gain
good traction europ five six instrument
commerci avail
recoveri nutrit adult pediatr market segment
high-single-digit low-double-digit revenu growth
establish pharmaceut factor drive higher
organ revenu growth
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-part
analysi valu report segment individu use
respect ev/ebitda multipl blend ev/ebitda
multipl ebitda estim billion
yield target key assumpt underli
valuat cc organ revenu growth
mid-single-digit growth basi point increas
oper margin year addit debt
reduct beyond contempl manag
guidanc price target impli price-to-earnings multipl
ep estim
arriv upsid scenario ev/ebitda multipl
ebitda estim billion key
differ base-cas assumpt mid-
high-single-digit cc organ revenu growth
basi point ebit margin expans year
due higher revenu growth faster realiz cost
synergi integr stj alr faster debt
downsid scenario ebitda
billion key differ base-cas assumpt
low- mid-single-digit cc organ revenu growth
basi point ebit margin expans
year due slower revenu growth slower
realiz cost synergi
sum-of-the-part valuat abt five major busi base ebitda estim
yield price target individu ev/ebitda multipl use valuat
diabet establish pharmaceut multipl along
ebitda estim busi give blend ev/ebitda estim
consolid ebitda billion target impli multipl
ep estim peer group evebitda price-to-earnings multipl large-cap med-tech
compani consensu estim price target basi
risk rate price target
face risk typic global diversifi healthcar compani impedi
price target rate includ competit currenc patent litig reimburs
clinic trial risk navig fda prolong econom slump
abbott laboratori one diversifi health care product compani
world product encompass intern brand gener drug devic diagnost
except ep fy dec
